Drugs / SHR-1501
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03995472 | Feb 2020 → Jan 2023 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04025957 | Oct 2019 → Jul 2022 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07073534 | Jul 2025 → Dec 2027 expected | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06588179 | Oct 2024 → Oct 2027 expected | non-invasive bladder urothelial carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05410730 | Nov 2022 → May 2025 overdue | non-invasive bladder urothelial carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07726992 | Aug 2026 → Dec 2029 expected | non-invasive bladder papillary urothelial neoplasm | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07424287 | Jul 2026 → Jun 2030 expected | urinary bladder carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07073534 ↗ |
| Known as | Il-15 super-agonist shr1501 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068589 ↗ |
| Route | Subcutaneous | “Administered subcutaneously” NCT03995472 ↗ |